WCN24-559 PROTOCADHERIN FAT1-POSITIVE MEMBRANOUS NEPHROPATHY SECONDARY TO HEMATOPOIETIC STEM-CELL TRANSPLANTATION SUCESSFULLY TREATED WITH RITUXIMAB

WCN24-559 PROTOCADHERIN FAT1-POSITIVE MEMBRANOUS NEPHROPATHY SECONDARY TO HEMATOPOIETIC STEM-CELL TRANSPLANTATION SUCESSFULLY TREATED WITH RITUXIMAB

Saved in:

Bibliographic Details
Main Authors:	Hugo Ferreira, Círia Sousa, Gil Brás, Luís Leite, Carlos Pinho Vaz, Marta Casal Moura, Sanjeev Sethi, José Maximino Costa
Format:	Article
Language:	English
Published:	Elsevier 2024-04-01
Series:	Kidney International Reports
Online Access:	http://www.sciencedirect.com/science/article/pii/S2468024924002249
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

De novo Membranous Nephropathy in Renal Allografts is Associated With Protocadherin FAT1
by: Laith F. Al-Rabadi, et al.
Published: (2025-01-01)

Epigenetic-Mediated Downregulation of μ-Protocadherin in Colorectal Tumours
by: Bujko Mateusz, et al.
Published: (2015-01-01)

Long-term Outcome of Adult Patients With Membranous Nephropathy Treated With Rituximab
by: Maria J. Vargas-Brochero, et al.
Published: (2025-08-01)

Donor-Cell Origin High-Risk Myelodysplastic Syndrome Synchronous with an Intracranial Meningioma-Like Tumor, 8 Years after Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Lymphocytic Leukemia
by: G. Brás, et al.
Published: (2017-01-01)

The complex role of protocadherin-19 in brain function: a focus on the oxytocin system
by: Sara Mazzoleni, et al.
Published: (2025-11-01)

Protocadherin 7 inhibits cell migration and invasion through E-cadherin in gastric cancer
by: Hong-Fang Chen, et al.
Published: (2017-04-01)

NF-Protocadherin Regulates Retinal Ganglion Cell Axon Behaviour in the Developing Visual System.
by: Louis C Leung, et al.
Published: (2015-01-01)

Obinutuzumab and Ofatumumab are More Effective Than Rituximab in the Treatment of Membranous Nephropathy Patients With Anti-Rituximab Antibodies
by: Maxime Teisseyre, et al.
Published: (2025-03-01)

Effectiveness of using rituximab in membranous nephropathy: a clinical case
by: I.M. Zavalna, et al.
Published: (2024-09-01)

Combination Therapy With Rituximab and Low-Dose Cyclophosphamide and Prednisone in Membranous Nephropathy
by: Coralien H. Vink, et al.
Published: (2024-12-01)

559 Improving social media advertising campaigns for participant recruitment for clinical trials and other health research studies
by: Elias Samuels, et al.
Published: (2025-04-01)

Mutations in protocadherin 15 and cadherin 23 affect tip links and mechanotransduction in mammalian sensory hair cells.
by: Kumar N Alagramam, et al.
Published: (2011-04-01)

Frequent long-range epigenetic silencing of protocadherin gene clusters on chromosome 5q31 in Wilms' tumor.
by: Anthony R Dallosso, et al.
Published: (2009-11-01)

WCN24-390 Combined Activity, Recovery, and Chronicity Kidney Biopsy Grading for Prognostic Assessment in ANCA-associated Vasculitis with Glomerulonephritis (AAV-GN)
by: Marta Casal Moura, et al.
Published: (2024-04-01)

Anti-Rituximab Antibodies Occurrence and Clinical Outcomes in Patients With Primary Membranous Nephropathy
by: Marco Allinovi, et al.
Published: (2025-08-01)

Rituximab treatment in non-lupus full-house nephropathy: A case report
by: Caroline Gee, et al.
Published: (2025-05-01)

A retrospective study of rituximab or Tacrolimus combined with glucocorticoid for idiopathic membranous nephropathy
by: LIU Chun-ling, et al.
Published: (2019-01-01)

Efficacy and safety of rituximab for membranous nephropathy in adults: a meta-analysis of RCT
by: Baike Mao, et al.
Published: (2025-04-01)

WCN25-4122 Rituximab in Primary Membranous Nephropathy- three years outcome
by: Prabjot Kaur Johal, et al.
Published: (2025-02-01)

P559: The impact of patient race and polygenic risk scores on genetic counselors’ risk assessment and management in breast cancer vignettes
by: Yifei Sylvia Lin, et al.
Published: (2025-01-01)

Diversity of clustered protocadherin-α genes in neuronal identity and its role in short-term specific associative memory formation
by: Tomoki Osuka, et al.
Published: (2025-06-01)

Retracted: Efficacy and Safety of Rituximab in the Treatment of Idiopathic Membranous Nephropathy: A Meta-Analysis
by: Applied Bionics and Biomechanics
Published: (2023-01-01)

Anti-Rituximab Antibodies in Primary Membranous Nephropathy: Time for Routine Monitoring in Clinical Practice?
by: Stathis Tsiakas, et al.
Published: (2025-08-01)

WCN25-4036 Improved Outcomes with an Additional Rituximab Dose in Primary Membranous Nephropathy
by: Vinod Kumar, et al.
Published: (2025-02-01)

“Normal” Glomerular Score Correlates With Outcomes in Antineutrophil Cytoplasmic Autoantibody–Associated Vasculitis With Glomerulonephritis
by: Marta Casal Moura, et al.
Published: (2025-02-01)

De Novo Exostosin-Associated Membranous Nephropathy in Kidney Transplant
by: Elisabeth P. Lafaut, et al.
Published: (2024-11-01)

Suppression of Pcdh8/paraxial protocadherin is required for efficient neighbor exchange in morphogenetic cell movement during zebrafish notochord formation
by: Masatake Kai, et al.
Published: (2024-10-01)

Rituximab for refractory idiopathic membranous nephropathy: a case report of 18-month follow-up
by: ZHANG Yi-de, et al.
Published: (2019-01-01)

High Temperature Requirement Protein A1–Positive Membranous Nephropathy in a Patient With Chronic Lymphocytic Leukemia
by: Ladan Zand, et al.
Published: (2025-05-01)

Efficacy and safety of a B-cell-driven rituximab regimen for the treatment of refractory idiopathic membranous nephropathy
by: Kaiqi Guo, et al.
Published: (2025-07-01)

Study on predictors for treatment efficacy of rituximab in patients with PLA2R-negative primary membranous nephropathy
by: XU Lili, HU Xiaofan, LI Hao, WANG Weiming
Published: (2025-06-01)

Membranous nephropathy associated with graft-versus-host disease in allogeneic bone marrow transplantation successfully treated with rituximab.
by: Jorge Quinchuela, et al.
Published: (2024-08-01)

Optimization of Rituximab Therapy in Adult Patients With PLA2R1-Associated Membranous Nephropathy With Artificial Intelligence
by: Alexandre Destere, et al.
Published: (2024-01-01)

Effect of low-dose rituximab on elderly patients with high risk membranous nephropathy： 2 cases and literature review
by: Zhao Xiao-yan, et al.
Published: (2025-02-01)

Effect of low-dose rituximab on elderly patients with high risk membranous nephropathy： 2 cases and literature review
by: Zhao Xiao-yan, et al.
Published: (2025-02-01)

Randomised, double-blind study to evaluate the efficacy of rituximab in the treatment of idiopathic membranous nephropathy: A clinical trial protocol.
by: Shinobu Shimizu, et al.
Published: (2025-01-01)

Visoko školstvo na području Riječko-senjske metropolije: Spomenica, uredio Mile Bogović, Kršćanska Sadašnjost - Teologija u Rijeci, Zagreb-Rijeka 1999., str. XVI+559.
by: Ivan Grah
Published: (2001-02-01)

WCN25-3929 RITUXIMAB VERSUS MODIFIED PONTICELLI REGIMEN IN THE MANAGEMENT OF PRIMARY MEMBRANOUS NEPHROPATHY IN A TERTIARY CARE CENTRE
by: VAISHNAVI KARNATI, et al.
Published: (2025-02-01)

A multicenter retrospective study on comparing the efficacy and safety of the therapy of intermittent cyclophosphamide and corticosteroids versus rituximab for primary membranous nephropathy
by: Yi Wang, et al.
Published: (2024-12-01)

The influence of high-fat diet and energy-restricted diet on hematopoietic stem cells: mechanisms and implications
by: Zhi’an Chen, et al.
Published: (2025-05-01)